Mazabraud Yann 4

What Happened
Yann Mazabraud, EVP and Head of International at Rhythm Pharmaceuticals (RYTM), received a grant of 23,350 restricted stock units (RSUs) on February 11, 2026. The RSUs were granted at $0.00 (typical for compensation awards) and represent contingent rights to receive one share of common stock per RSU when vested.

Key Details

• Transaction date: 2026-02-11; filing date (Form 4): 2026-02-13 (filed within the normal 2-business-day window).
• Award: 23,350 RSUs, acquisition price reported as $0.00 (derivative award).
• Vesting (per footnote): 25% of the RSUs vest on each of March 1, 2027; Feb 1, 2028; Feb 1, 2029; and Feb 1, 2030. RSUs have no expiration date.
• Footnote F1: each RSU = right to one share upon vesting.
• Shares owned after the transaction: not disclosed in the provided filing excerpt.

Context
This was a compensation grant (an award), not an open-market purchase or sale — such awards are common for executives and are meant to align long-term incentives. Because these are RSUs, no shares are issued until vesting conditions are met; they therefore do not indicate an immediate buying or selling signal.